ID   SJ-HGGX6c
AC   CVCL_C1NM
SY   SJHGG009103_C8
DR   cancercelllines; CVCL_C1NM
DR   Wikidata; Q114313027
RX   PubMed=34215733;
WW   https://pbtp.stjude.cloud/sample-details/29960/baker/SJHGG009103/SJ-HGGX6/Cell%20Line
CC   Characteristics: Derived from a patient-derived xenograft.
CC   Doubling time: 5.6 days (PubMed=34215733).
CC   Sequence variation: Mutation; HGNC; 886; ATRX; Simple; p.Thr1582fs (c.4745delA); Zygosity=Heterozygous (PubMed=34215733).
CC   Sequence variation: Mutation; HGNC; 4764; H3-3A; Simple; p.Gly35Arg (c.103G>A) (H3.3G34R); ClinVar=VCV000438766; Zygosity=Heterozygous (PubMed=34215733).
CC   Sequence variation: Mutation; HGNC; 25311; H3C13; Simple; p.Ser88Pro (c.262T>C); Zygosity=Heterozygous (PubMed=34215733).
CC   Sequence variation: Mutation; HGNC; 8803; PDGFRA; Simple; p.Asp583_Trp586del (c.1749_1760del); Zygosity=Heterozygous (PubMed=34215733).
CC   Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg273Cys (c.817C>T); ClinVar=VCV000043594; Zygosity=Homozygous (PubMed=34215733).
CC   Genetic integration: Method=Transfection/transduction; Gene=UniProtKB; P08659; Firefly luciferase.
CC   Genetic integration: Method=Transfection/transduction; Gene=FPbase; 8DNLG; YFP (Note=EYFP, yellow fluorescent protein derived from GFP).
CC   Omics: Deep exome analysis.
CC   Omics: Transcriptome analysis by RNAseq.
CC   Derived from site: In situ; Brain, cerebral cortex; UBERON=UBERON_0000956.
ST   Source(s): PubMed=34215733
ST   Amelogenin: X
ST   CSF1PO: 12
ST   D13S317: 12
ST   D16S539: 12,13
ST   D18S51: 12,16
ST   D21S11: 32.2
ST   D3S1358: 16,18
ST   D5S818: 11,12
ST   D7S820: 10,14
ST   D8S1179: 10,15
ST   FGA: 23,25
ST   Penta D: 9,13
ST   Penta E: 11,14
ST   TH01: 7,9.3
ST   TPOX: 11
ST   vWA: 14,15
DI   NCIt; C3058; Glioblastoma
DI   ORDO; Orphanet_360; Glioblastoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
SX   Female
AG   16-17Y
CA   Cancer cell line
DT   Created: 22-09-22; Last updated: 10-09-24; Version: 6
//
RX   PubMed=34215733; DOI=10.1038/s41467-021-24168-8; PMCID=PMC8253809;
RA   He C., Xu K., Zhu X.-Y., Dunphy P.S., Gudenas B., Lin W.-W., Twarog N.,
RA   Hover L.D., Kwon C.-H., Kasper L.H., Zhang J.-Y., Li X.-Y., Dalton J.,
RA   Jonchere B., Mercer K.S., Currier D.G., Caufield W., Wang Y.-Z., Xie J.,
RA   Broniscer A., Wetmore C., Upadhyaya S.A., Qaddoumi I., Klimo P.,
RA   Boop F., Gajjar A., Zhang J.-H., Orr B.A., Robinson G.W., Monje M.,
RA   Freeman B.B. 3rd, Roussel M.F., Northcott P.A., Chen T.-S., Rankovic Z.,
RA   Wu G., Chiang J.C.-H., Tinkle C.L., Shelat A.A., Baker S.J.;
RT   "Patient-derived models recapitulate heterogeneity of molecular
RT   signatures and drug response in pediatric high-grade glioma.";
RL   Nat. Commun. 12:4089.1-4089.17(2021).
//